Federal appeals court refuses to hear stem cell donor ruling

In December, a panel of the 9th US Circuit Court of Appeals in California unanimously ruled that because stem cells can be harvested from peripheral blood, that donating them is more akin to blood donation than to organ donation. Consequently, it should be legal to offer financial incentives to donors and should not be considered against the law in accord with the National Organ Transplant Act.

This week, a federal appeals court that was asked to reconsider the ruling has refused, with not a single one of the 25 active judges in support of another hearing.

The US Justice Department has 90 days to appeal the ruling to the US Supreme Court.

Proponents believe that incentives will bring more donors to the National Bone Marrow Program Registry, something that is desperately needed because so many ethnicities are under-represented in the registry. Opponents meanwhile argue that such incentives could lead to exploitation or to a rise in costs of bone marrow transplants so that only the wealthy can afford them.

Source: MedPage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap